Long-Term Data Confirms Immunotherapy Benefits
A five-year follow-up study has found that combination immunotherapy sustained a 49% reduction in melanoma recurrence among patients with advanced skin cancer. The results, published in the New England Journal of Medicine, provide the longest-term evidence to date for the effectiveness of combining two checkpoint inhibitor drugs in high-risk melanoma patients.
The study followed 423 patients with stage III or IV melanoma who had undergone surgical removal of their tumors. Patients received either a combination of nivolumab and ipilimumab, or one of the drugs alone. After five years, the combination therapy group showed a 49% lower risk of recurrence compared to patients who received only nivolumab. The benefit was seen across all patient subgroups, including those with BRAF mutations.
Treatment Comes With Side Effects
The combination therapy was not without risks. Patients in the combination group experienced higher rates of immune-related side effects, including colitis, hepatitis, and pneumonitis. However, most side effects were manageable with corticosteroids, and no treatment-related deaths were reported in the study.
Researchers noted that the side effect profile was consistent with previous shorter-term studies. They emphasized that the benefits of reduced recurrence risk outweigh the risks for patients with high-risk melanoma. The study's lead author said the results should help doctors and patients make more informed decisions about treatment options.
Implications for Skin Cancer Treatment
Melanoma is the most dangerous form of skin cancer, and incidence rates have been rising globally. The combination of nivolumab and ipilimumab works by blocking proteins that cancer cells use to evade the immune system, allowing T cells to attack tumors more effectively.
The five-year data could lead to expanded use of combination immunotherapy as a standard treatment for high-risk melanoma patients. Currently, many patients receive a single immunotherapy drug. The study suggests that combination therapy, despite its higher side effect rate, offers substantially better long-term protection against recurrence. Skin cancer experts called the results practice-changing and urged updated clinical guidelines.